Evidence map›Paper›PMID 30285653›Full record

ArticleBMC infectious diseases2018

Development of a sandwich ELISA to detect Leishmania 40S ribosomal protein S12 antigen from blood samples of visceral leishmaniasis patients.

Wen-Wei Zhang, Ayan Kumar Ghosh, Raodoh Mohamath, Jacqueline Whittle, Alessandro Picone, Patrick Lypaczewski, Momar Ndao, Randall F Howard, Pradeep Das, Steven G Reed and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Molecular Tracking of theFrontiers in cellular and infection microbiology · 2021
    Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Wen-Wei ZhangDepartment of Microbiology and Immunology, McGill University, 3775 University Street, Montreal, Quebec, H3A2B4, Canada.
Ayan Kumar GhoshRajendra Memorial Research Institute of Medical Sciences (ICMR), Patna, Bihar, India.
Raodoh MohamathInfectious Disease Research Institute, Seattle, WA, USA.
Jacqueline WhittleInfectious Disease Research Institute, Seattle, WA, USA.
Alessandro PiconeInfectious Disease Research Institute, Seattle, WA, USA.
Patrick LypaczewskiDepartment of Microbiology and Immunology, McGill University, 3775 University Street, Montreal, Quebec, H3A2B4, Canada.
Momar NdaoNational Reference Center for Parasitology, The Research Institute of the McGill University Health Center, Montreal, Quebec, Canada.
Randall F HowardInfectious Disease Research Institute, Seattle, WA, USA.
Pradeep DasRajendra Memorial Research Institute of Medical Sciences (ICMR), Patna, Bihar, India.
Steven G ReedInfectious Disease Research Institute, Seattle, WA, USA.
Greg MatlashewskiDepartment of Microbiology and Immunology, McGill University, 3775 University Street, Montreal, Quebec, H3A2B4, Canada. greg.matlashewski@mcgill.ca.
Infectious Disease Research Institute · USMcGill University · CARajendra Memorial Research Institute of Medical Sciences · INMcGill University Health Centre · CA

Funding

Bill and Melinda Gates Foundation OPP49932 and OPP1084251Institute of Infection and Immunity 236334
6 · The paper itself

Abstract

backgroundVisceral leishmaniasis (VL), caused by Leishmania donovani complex parasites, is a neglected parasitic disease that is generally fatal if untreated. Despite decades of research to develop a sensitive VL diagnostic test, definitive diagnosis of VL still mainly relies on the visualization of the parasite in aspirates from the spleen, liver or bone marrow, an invasive and dangerous process with variable sensitivity. A sensitive assay that can detect Leishmania antigen from blood samples will help confirm cause, cure or recurrence of VL.

methodsIn this study, rabbit polyclonal antibodies were raised against eight recombinant Leishmania proteins that are highly abundant in Leishmania. The antibodies were purified and labeled with biotin for developing a prototype sandwich enzyme-linked immunosorbent assay (ELISA).

resultsThe ELISA for the Leishmania 40S ribosomal protein S12 detected target antigen with the highest sensitivity and specificity and could detect 1 pg of purified protein or as few as 60 L. donovani parasites. The 40S ribosomal protein S12 sandwich ELISA could detect the target antigen from Peripheral Blood Mononuclear Cell (PBMC) samples in 68% of VL patients and post-kala-azar dermal leishmaniasis (PKDL) patients, providing an estimation of parasitemia ranging from 15 to 80 amastigotes per ml of blood.

conclusionThese results indicate that the 40S ribosomal protein S12 sandwich ELISA warrants further tests with more clinical samples of VL patients and other parasitic diseases. It is hopeful that this ELISA could become a useful tool for confirming VL diagnosis, monitoring treatment progress, disease recurrence and possibly detecting asymptomatic Leishmania infections with a high parasite load.

Indexed as

AdolescentAdultAnimalsAntigens, ProtozoanAsymptomatic InfectionsCase-Control StudiesEnzyme-Linked Immunosorbent AssayFemaleHumansLeishmaniaLeishmaniasisLeishmaniasis, VisceralLeukocytes, MononuclearMaleMiddle AgedNeglected DiseasesAntigens, ProtozoanRibosomal Proteinsribosomal protein S1240S ribosomal protein S12DiagnosisELISAPBMCVisceral Leishmaniasis

Identifiers

PMID30285653
PMCPMC6171325
OpenAlexW2895440587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.